NCT05858853View on ClinicalTrials.gov

Phase II/III of Recombinant Human Serum Albumin

PHASE2/PHASE3CompletedINTERVENTIONAL
Enrollment

92

Participants

Timeline

Start Date

May 24, 2023

Primary Completion Date

September 15, 2023

Study Completion Date

September 15, 2023

Conditions
Hepatic Ascites
Interventions
DRUG

Recombinant Human Serum Albumin

The experimental drug (recombinant human serum albumin injection) was administered 10 g/ day for 14 days

DRUG

Recombinant Human Serum Albumin

The experimental drug (recombinant human serum albumin injection) was administered 20 g/ day for 7 days

DRUG

Human serum albumin

Control drug (human blood albumin injection) 10 g/ day for 14 days

DRUG

Human serum albumin

Control drug (human blood albumin injection) 20 g/ day for 7 days

Trial Locations (1)

10084

Shenzhen Protgen Ltd, Guangdong

All Listed Sponsors
lead

Protgen Ltd

INDUSTRY

NCT05858853 - Phase II/III of Recombinant Human Serum Albumin | Biotech Hunter | Biotech Hunter